Author

E. M. Swisher

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 4

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Research Focus:drug response / drug discovery· 3 Assay:bulk RNA-seq· 2 Research Focus:cell type annotation· 2 Research Focus:differential expression· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:DNA methylation· 1

Frequent Co-Authors

M. R. Radke· 3 shared A. Dobrovic· 2 shared C. L. Scott· 2 shared K. Nesic· 2 shared M. I. Harrell· 2 shared M. J. Wakefield· 2 shared O. Kondrashova· 2 shared R. M. Hurley· 2 shared

Activity by Year

2017-2021 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

M. R. Radke

Mutual co-authors in cluster

Author profile →

4 papers

Recent·Most cited

Specific BRCA and immune configurations determine optimal response to platinum-based chemotherapy in triple negative breast and ovarian carcinomas

F. Menghi, K. Banda, P. Kumar, R. Straub, L. Dobrolecki, I. V. Rodriguez, S. E. Yost, H. Chandok, M. R. Radke, A. S. Zhu, G. Somlo, Y. Yuan, M. T. Lewis, E. M. Swisher, E. T. Liu

This study identifies that BRCA1 promoter methylation (BRCA1meth) leads to adaptive recovery of BRCA1 expression and poorer response to platinum chemotherapy compared to BRCA mutations, while immune signals enhance response in BRCA-proficient cancers.

bioRxiv · Aug 19, 2021 · PreprintCancer Biology

Characterization of a RAD51C-Silenced High Grade Serous Ovarian Cancer Model During PARP Inhibitor Resistance Development

R. M. Hurley, C. D. McGehee, K. Nesic, C. Correia, T. M. Weiskittel, R. L. Kelly, A. Venkatachalam, X. Hou, N. M. Pathoulas, X. W. Meng, O. Kondrashova, M. R. Radke, P. A. Schneider, K. S. Flatten, K. L. Peterson, , S. H. Kaufmann

This study shows that PARPi treatment can reverse RAD51C promoter methylation and restore expression in a high-grade serous ovarian cancer model, while maintaining platinum sensitivity.

bioRxiv · Dec 25, 2020Cancer Biology

Acquired RAD51C promoter methylation loss causes PARP inhibitor resistance in high grade serous ovarian carcinoma

K. Nesic, O. Kondrashova, R. M. Hurley, C. McGehee, C. J. Vandenberg, G.-Y. Ho, E. Lieschke, G. Dall, N. Bound, K. Shield-Artin, M. R. Radke, A. Musafer, Z. Qing Chai, M. R. Eftekhariyan Ghamsari, M. I. Harrell, , C. L. Scott

This study shows that loss of RAD51C promoter methylation leads to PARP inhibitor resistance in high-grade serous ovarian carcinoma, independent of BRCA1 methylation status.

bioRxiv · Dec 10, 2020Cancer Biology

Genome-wide and high-density CRISPR-Cas9 screens identify point mutations in PARP1 causing PARP inhibitor resistance

S. J. Pettitt, D. B. Krastev, I. Brandsma, A. Drean, F. Song, R. Aleksandrov, M. I. Harrell, M. Menon, R. Brough, J. Campbell, J. Frankum, M. Ranes, H. N. Pemberton, R. Rafiq, K. Fenwick, , C. J. Lord

The paper identifies PARP1 point mutations causing PARP inhibitor resistance through CRISPR-Cas9 screens and shows their impact on PARP1 trapping and chemotherapy sensitivity.

bioRxiv · Oct 14, 2017Cancer Biology